Nazione: Australia
Lingua: inglese
Fonte: Department of Health (Therapeutic Goods Administration)
mesalazine, Quantity: 1200 mg
Takeda Pharmaceuticals Australia Pty Ltd
Mesalazine
Tablet, modified release
Excipient Ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; Carnauba Wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate
Oral
12 tablets, 120 tablets, 60 tablets
(S4) Prescription Only Medicine
For the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.
Visual Identification: Red-brown, ellipsoidal, film-coated tablet, S476 debossed on one side; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Registered
2009-09-25
MEZAVANT ® M E Z A V A N T ® C M I V 3 . 0 CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. WHY AM I USING MEZAVANT? MEZAVANT contains the active ingredient mesalazine. MEZAVANT is used for the treatment of ulcerative colitis. For more information, see Section 1. Why am I using MEZAVANT? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I USE MEZAVANT? Do not use if you have ever had an allergic reaction to MEZAVANT or any of the ingredients listed at the end of the CMI. Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding. For more information, see Section 2. What should I know before I use MEZAVANT? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with MEZAVANT and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I USE MEZAVANT? • Your doctor will tell you what dose to take each day. • Take your tablets with or without food at the same time each day. The tablets must be swallowed whole and must not be crushed or chewed. Follow all directions given to you by your pharmacist or doctor carefully. More instructions can be found in Section 4. How do I use MEZAVANT? in the full CMI. 5. WHAT SHOULD I KNOW WHILE USING MEZAVANT? THINGS YOU SHOULD DO • Remind any doctor or dentist you visit that you are using MEZAVANT. If you are pregnant or intend to become pregnant while using this medicine, tell the doctor immediately. THINGS YOU SHOULD NOT DO • Do not stop using this medicine suddenly or change the dosage without checking with your doctor. DRIVING OR USING MACHINES • MEZAVANT is unlikely to have any effect on your ability to drive or use machines. LOOKING AFTER YOUR MEDICINE • Store MEZAVANT in a cool dry place where the temperature is below 25°C. For more information, Leggi il documento completo
MEZAVANT PI V4.0(CCDS V24) 1 AUSTRALIAN PRODUCT INFORMATION MEZAVANT ® (MESALAZINE) PROLONGED RELEASE TABLET 1 NAME OF THE MEDICINE Mesalazine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION MEZAVANT contains 1.2 g of the active ingredient mesalazine. The MEZAVANT tablet contains a core of mesalazine (5-aminosalicylic acid), 1.2 g, formulated in a multi-matrix system. This system is coated with methacrylic acid copolymers, Type A and Type B, which are designed to dissolve at approximately pH 7. The matrix of lipophilic and hydrophilic excipients facilitates the extended delivery of effective concentrations of mesalazine through the entire colon with limited systemic absorption. For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Gastro-resistant, prolonged release tablets. APPEARANCE The tablets are presented as red-brown, ellipsoidal, film-coated tablets, debossed on one side with S476. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis. 4.2 DOSE AND METHOD OF ADMINISTRATION DOSAGE MEZAVANT is intended for once daily, oral administration. ADULTS, INCLUDING THE ELDERLY (>65 YEARS) For induction of remission: 2.4 to 4.8 g (two to four tablets) should be taken once daily. For maintenance of remission: 2.4 g (two tablets) should be taken once daily. MEZAVANT PI V4.0(CCDS V24) 2 CHILDREN AND ADOLESCENTS MEZAVANT is not recommended for use in children below the age of 18 years due to a lack of data on safety and efficacy. METHOD OF ADMINISTRATION For oral administration. MEZAVANT tablets must not be crushed or chewed and should be swallowed whole with or without food. DOSAGE ADJUSTMENT Specific studies have not been performed to investigate MEZAVANT in patients with hepatic or renal impairment, dialysis or concomitant disease. MONITORING ADVICE The highest dose of 4.8 g/day is recommended for patients not responding to lower doses of mesalazine. When using the highest dose (4. Leggi il documento completo